Medication-info.com Search Menu

Cinqair (Reslizumab): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Boxed warning
Strength:
10 mg/mL
Drug class:
Active ingredient:
Similar drugs:

Source: FDA drug labeling via NLM DailyMed · About this document

Patient information: uses, side effects, how to take - Cinqair

What is the most important information I should know about CINQAIR?

CINQAIR can cause serious side effects, including:

Serious allergic reactions (anaphylaxis). Serious allergic reactions can happen right after you receive your CINQAIR infusion. These reactions can cause death. Allergic reactions sometimes do not happen right away. Your healthcare provider will watch you during and after you receive your CINQAIR infusion for any signs of a reaction. Tell your healthcare provider right away if you have any of the following symptoms that may be associated with an allergic reaction:

  • breathing problems • flushing • itching • symptoms of low blood pressure (fainting, dizziness, light headedness, confusion, fast heart beat)
  • paleness • skin rash (hives) • swelling of your face, lips, mouth, or tongue • nausea or abdominal discomfort

What is CINQAIR?

CINQAIR is a prescription medicine used with other asthma medicines for the maintenance treatment of asthma in people aged 18 years of age and older whose asthma is not controlled with the current asthma medicines. When added to other medicines for asthma, CINQAIR helps prevent severe asthma attacks (exacerbations) and can improve your breathing. Medicines such as CINQAIR reduce blood eosinophils. Eosinophils are a type of white blood cell that may contribute to your asthma.

  • CINQAIR is not used to treat other problems caused by eosinophils.
  • CINQAIR is not used to treat sudden breathing problems.

It is not known if CINQAIR is safe and effective in children less than 18 years of age.

Do not receive CINQAIR if you are allergic to reslizumab or any of the ingredients in CINQAIR. See the end of this leaflet for a complete list of ingredients in CINQAIR.

Before receiving CINQAIR, tell your healthcare provider about all of your medical conditions, including if you:

  • are taking oral or inhaled corticosteroid medicines. Do not stop taking your corticosteroid unless your healthcare provider tells you to stop. This may cause other symptoms that were controlled by the corticosteroid medicine to come back.
  • have or have had cancer (malignancy).
  • have a parasitic (helminth) infection.

  • are pregnant or plan to become pregnant. It is not known if CINQAIR will harm your unborn baby. Tell your healthcare provider if you become pregnant during your treatment with CINQAIR.

  • are breastfeeding or plan to breastfeed. It is not known if CINQAIR passes into your breast milk. You and your healthcare provider should decide if you will receive CINQAIR and breastfeed. Talk to your healthcare provider about the best way to feed your baby if you receive CINQAIR.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Do not stop taking your other asthma medicines unless your healthcare provider tells you to.

How will I receive CINQAIR?

  • You will be given CINQAIR by a healthcare provider using a needle placed in a vein (intravenous infusion) 1 time every 4 weeks. It will take about 20 to 50 minutes to receive the full dose of CINQAIR.

What are the possible side effects of CINQAIR?

CINQAIR may cause serious side effects, including:

  • See “What is the most important information I should know about CINQAIR?”
  • abnormal growth of cells or tissue in your body that may or may not be cancer (malignancy)

The most common side effects of CINQAIR include throat pain.

These are not all the possible side effects of CINQAIR.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of CINQAIR.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use CINQAIR for a condition for which it was not prescribed. You can ask your pharmacist or healthcare provider for information about CINQAIR that is written for healthcare professionals.

What are the ingredients in CINQAIR?

Active ingredient: reslizumab

Inactive ingredients: sodium acetate, acetic acid, sucrose

Manufactured by: Teva Respiratory, LLC; West Chester, PA 19380

U.S. License Number 2047

©2020 Teva Respiratory, LLC

CNQPL-003

For more information, go to www.CINQAIR.com or call 1-888-483-8279.

This Patient Information has been approved by the U.S. Food and Drug Administration

Revised: 02/2020

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: BLA 761033 · View the label on DailyMed

Revision date stated in the text: February 2020

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Cinqair

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Boxed warning Yes – this drug has a boxed warning (also called a black box warning), the strongest warning of the FDA.
Drug class Interleukin-5 Antagonist
Active ingredient Reslizumab 10 mg/mL
Dosage form Injection, solution, concentrate
Route Intravenous
Marketing status listed in the FDA NDC Directory
Company (applicant) TEVA RESPIRATORY LLC
FDA approval BLA 761033Biologics License Application (BLA) Approved March 23, 2016
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
10 mg/mL – 10 ml in 1 vial, single-use / 1 in 1 carton NDC 59310-610-31
10 mg/mL – 10 ml in 1 vial, single-use / 1 in 1 carton NDC 59310-610-33

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.